^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LNK101

    i
    Other names: LNK101
    Company:
    Link Immunotherap
    Drug class:
    CD3 agonist, Mesothelin inhibitor
    Related drugs:
    over2years
    T Cell Engaging Bispecific Antibodies Produce Durable Response in Mesothelin-Positive Patient-Derived Xenograft Models of Pediatric AML (ASH 2021)
    Antibody single-chain variable region (scFv) sequences derived from amatuximab recognizing MSLN and from either blinatumomab or AMG330 targeting CD3 were used to engineer and express two MSLN/CD3-targeting BsAbs: MSLN AMA -CD3 L2K and MSLN AMA -CD3 AMG respectively...Chemotherapy (DA) consisted of 3 doses of 1.5 mg/kg daunorubicin iv and 5 doses of 50 mg/kg cytarabine ip...Conclusion These data validate the efficacy of MSLN-targeting BsAbs in PDX models with endogenous MSLN expression. Because prior MSLN-directed therapies appeared safe in humans, MSLN-targeting BsAbs could be ideal immunotherapies for MSLN-positive pediatric AML patients.
    Preclinical • IO biomarker
    |
    MSLN (Mesothelin) • B2M (Beta-2-microglobulin)
    |
    MSLN expression • MSLN overexpression • MSLN positive
    |
    cytarabine • Blincyto (blinatumomab) • daunorubicin • LNK101 • amatuximab (MORAb-009) • eluvixtamab (AMG 330)